

US008383843B2

(12) United States Patent

Wang et al.

(54) METHOD FOR PREPARING A COUMARIN COMPOUND, CHROMENE COMPOUND, AND METHOD FOR PREPARING A CHROMENE COMPOUND

- (75) Inventors: Eng-Chi Wang, Kaohsiung (TW);
 Jui-Chi Tsai, Taipei (TW); Sie-Rong Li, Taipei County (TW); Po-Yuan Chen, Kaohsiung County (TW)
- (73) Assignee: Kaohsiung Medical University, Kaohsiung (TW)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 42 days.
- (21) Appl. No.: 12/901,647
- (22) Filed: Oct. 11, 2010
- (65) **Prior Publication Data**

US 2012/0088923 A1 Apr. 12, 2012

- (51) Int. Cl. *C07D 311/00* (2006.01)
- (52) U.S. Cl. 549/399; 549/404

(56) **References Cited**

PUBLICATIONS

Tsai et al. J. Org. Chem., 2009, 74 (22), pp. 8798-8801.*

* cited by examiner

Primary Examiner - Nizal Chandrakumar


(10) Patent No.: US 8,383,843 B2

(45) **Date of Patent:** Feb. 26, 2013

(74) Attorney, Agent, or Firm—Fox Rothschild, LLP; Robert J. Sacco


(57) **ABSTRACT**

Disclosed herein is a method for preparing a coumarin compound of formula (F), in which R^1 , R^2 , and R^3 are independently H, $C_1 \sim C_7$ alkoxy, $C_1 \sim C_7$ alkyl, phenoxy, benzyloxy, or a halogen atom; R^4 is an alkyl group; and Ar is an optionally substituted aryl group,



(E)

the method including: treating a chromene compound having the following formula (E)



with an acid in the presence of water.

A chromene compound of formula (E) and a method for preparing the chromene compound of formula (E) are also disclosed.

7 Claims, No Drawings

45

METHOD FOR PREPARING A COUMARIN COMPOUND, CHROMENE COMPOUND, AND METHOD FOR PREPARING A CHROMENE COMPOUND


BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to a method for preparing a coumarin compound, a chromene compound, and a method for preparing the chromene compound.


2. Description of the Related Art

Coumarins and derivatives thereof have biological activities including anti-carcinogenic activity, fungicidal activity, 15 anti-coagulant activity, etc. For example, coumarin-3-(Naryl) sulfonamides (see the following formula (I)) exhibit anticancer activity (see N. S. Reddy et al., Bioorg. Med. Chem. Lett. 14 (2004) 4093-4097 and Coumarin-3 (N-aryl) carboxamides (see the following formula (II)) can be used to $_{20}$ arrest growth of breast cancer cells (see N. S. Reddy at al., Bioorg. Med. Chem. 13 (2005), 3141-3147).




In formula (I), X^1 is 4-OCH₃, 3-OH, 4-F, or 4-Br; and Y^1 is 8-Br, 8-Cl, 8-OCH₃, 8-OC₂H₅; in formula (II), X² is H, 8-C₂H₅O, 6-Br, or 6-Cl; and Y² is 4-Br, 4-I, 4-Cl, 3-NO₂, or 3-NH₂.

Another coumarin derivative known in the art is 3-methoxymethyl coumarin, which can be prepared from 3-chloromethyl coumarin by the following reaction (see J. Org. Chem., 1960, 25 (10), pp 1713-1716):



Preparation of 3-methoxymethyl coumarin can also be 65 conducted by the following reaction (see J. Org. Chem., 1962, 27 (2), pp 696-698),






However, trifluoroacetic acid is extremely corrosive and generates a poisonous gas in the reaction, and chloromethyl ether (ClCH₂OR) is a carcinogenic substance. Hence, the use of these compounds is likely to result in safety and health concerns.

Therefore, there is a need in the art to develop a process that is simple and safe in the preparation of a coumarin compound.

SUMMARY OF THE INVENTION

The object of the present invention is to provide a method for preparing a coumarin compound, a chromene compound, and a method for preparing the chromene compound.


30 According to one aspect of this invention, there is provided a method for preparing a coumarin compound of formula (F), in which R^1 , R^2 , and R^3 are independently H, $C_1 \sim C_7$ alkoxy, C1~C7 alkyl, phenoxy, benzyloxy, or a halogen atom; R4 is an alkyl group; and Ar is an optionally substituted aryl group,



(F)

(E)

the method comprising: treating a chromene compound having the following formula (E)



with an acid in the presence of water.

According to another aspect of this invention, there is provided a chromene compound of formula (E):


40

45

55

(E)


(E)



3

wherein R¹, R², R³, R⁴, Ar have the same definitions as the aforesaid R^1 , R^2 , R^3 , R^4 , and Ar.

According to yet another aspect of this invention, there is provided a method for preparing the aforesaid chromene 15 compound of formula (E), including reacting 3-cyanochromene of formula (B):




with R⁴OX and ArNH₂ in she presence of a solvent,

wherein, R¹, R², and R³ in formula (B), R⁴ in R⁴OX, and Ar in ArNH₂ have the same definitions as R^1 , R^2 , R^3 , R^4 , and Ar $_{30}$ in formula (E); and X in R⁴OX is Na or K.

DETAILED DESCRIPTION OF THE PREFERRED **EMBODIMENTS**

35 In this invention, the applicants endeavored to develop a simple and safe strategy for the synthesis of a coumarin compound.

Accordingly, this invention provides a chromene compound of formula (E):



wherein R^1 , R^2 , and R^3 are independently H, $C_1 \sim C_7$ alkoxy, $C_1 \sim C_7$ alkyl, phenoxy, benzyloxy, or a halogen atom; R⁴ is an alkyl group; and Ar is an optionally substituted aryl group.


According to the preferred embodiments of this invention, R^1 , R^2 and R^3 are independently H, Cl, Br, benzyloxy (OBn), or methoxy (OMe).

Preferably, R^4 is a C_1 - C_4 alkyl group. In the examples of this invention, R⁴ is methyl (Me), ethyl (Et), i-propyl (i-Pr), or 60 n-butyl (n-Bu).

Preferably, Ar is unsubstituted aryl, haloaryl alkylaryl, or alkoxyaryl. Examples of the unsubstituted aryl include, but are not limited to, phenyl (Ph) and naphthyl. Haloaryl is preferably halophenyl, and examples thereof include, but are 65 not limited to, 4-fluoro-phenyl(4-FPh), 4-chloro-phenyl (4-ClPh), 4-bromo-phenyl (4-BrPh), 3-chloro-phenyl

(3-ClPh), and 3-bromo-phenyl (3-BrPh). Alkylaryl is preferably alkylphenyl and examples thereof include, but are not limited to, 4-methyl-phenyl (4-MePh), 3-methyl-phenyl (3-MePh), 2-methyl-phenyl (2-MePh), 5-methyl-phenyl (5-MePh), and 6-methyl-phenyl (6-MePh). Alkoxyaryl is preferably alkoxyphenyl and examples thereof include, but are not limited to, 4-methoxy-phenyl (4-OMePh), 3-methoxy-phenyl (3-OMePh), 2-methoxy-phenyl (2-OMePh), 5-methoxy-phenyl (5-OMePh), and 6-methoxy-phenyl 10 (6-OMePh). In the examples of this invention, Ar is phenyl, 4-fluoro-phenyl, 4-chloro-phenyl, 4-bromo-phenyl, 4-methyl-phenyl, 4-methoxy-phenyl, or 3-methoxy-phenyl.


The compound of formula (E) can be reacted with an acid in the presence of water so as to prepare a coumarin compound of formula (F):



wherein R¹, R², R³, and R⁴ in formula (F) have the same definitions as R^1 , R^2 , R^3 , and R^4 in formula (E).

The acid and water used in the method for preparing the coumarin compound of formula (F) can provide H₃O⁺ to convert C-N-Ar into C-O. Examples of the acid include HCl, HBr, HI, CH₃CO₂H, and combinations thereof. In one preferred embodiment of this invention, the acid is HCl.

Preferably, the chromene compound of formula (E) is prepared by reacting 3-cyanochromene represented formula (B) with R⁴OX and ArNH₂ in the presence of a solvent,



wherein R^1 , R^2 , R^3 , R^4 and Ar are as defined above; and X $_{50}$ is Na or K.

Preferably, the solvent used for preparing the chromene compound of formula (E) is selected from the group consisting of R⁵OH and tetrahydrofuran (THF), wherein R⁵ is $C_1 \sim C_4$ alkyl.

Preferably, the reaction in the method for preparing the chromene compound of formula (E) is conducted under a reflux condition.


In the preferred embodiments of this invention, 3-cyanochromene of formula (B) is 3-cyano-2H-chromene (B_1) , 6-chloro-3-cyano-2H-chromene (B2), 6-bromo-3-cyano-2Hchromene (B_3) , 7-benzyloxy-3-cyano-2H-chromene (B_4) , 7-methoxy-3-cyano-2H-chromene (B₅, or 8-methoxy-3-cyano-2H-chromene (B_6).

3-cyanochromene of formula (B) may be prepared by conventional techniques. Preferably, 3-cyanochromene is prepared by reacting salicylaldehyde of formula (A) with acrylonitrile in the presence of a catalyst:

(F)




(A)




wherein R¹, R², and R³ are as defined above. In the preferred embodiments of this invention, salicylaldehyde of formula ¹⁰ (A) is salicylaldehyde (A₁), 5-chlorosalicylaldehyde (A₂), 5-chlorosalicylaldehyde (A₃), 4-benzyloxysalicylaldehyde (A₄), 4-methyloxysalicylaldehyde (A₅), or 3-methyloxysalicylaldehyde (A₆).

Preferably, the catalyst is 1,4-diazabicyclo[2,2,2]octane 15 (DABCO), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), trimethylamine, triethylamine, or triphenylphosphine (TPP).

In the preferred embodiments of this invention, the method for preparing the coumarin compound of formula (F) includes reactions in the following sequence:





It is noted that $ArNH_2$ (hereinafter referred to as compound (D)) formed as a byproduct of the last reaction can be recycled as the reagent for the reaction of preparing the chromene compound of formula (E). In the aforesaid series of reactions, the reagents and the materials thus used are safe and are commercially available. The coumarin compound of formula (F) can be easily and safely obtained by reacting the chromene compound of formula (E) with an acid.

²⁰ The following examples are provided to illustrate the merits of the preferred embodiments of the invention, and should not be construed as limiting the scope of the invention.

EXAMPLES

The compounds prepared in the following Examples 1-36 were measured by structure identification using the following general procedures.

General Procedures:

- 1. The melting point was detected using a micro meltingpoint apparatus (available from Yanaco company).
- ¹H-NMR and ¹³C-NMR spectra were detected using a Varian Unity-400 spectrometer.
- 3. IR spectra were measured in a Perkin Elmer system 2000 FT-IR spectrometer.
- 4. Elemental analysis was recorded in an element analyzer (trade name: Elementar vario EL III).
- 5. Mass analysis was measured in a mass spectrometer (trade name: Bruker APEX II).
- Before the examples are illustrated, the species of the starting materials of compounds (A), the intermediate chromene compounds (B) and (E), the reagents (C) of R⁴ONa and (D) of ArNH², and the final products of coumarin compounds (F), as well as the substituted groups of R¹, R², R³, and R⁴ in Examples 1-36 are listed in Table 1 for the sake of clarity.

TABLE 1

Ex	Target	Reactants				Substituted groups of compound (E) or (F)					
No.	compound	Α	в	С	D	Е	\mathbb{R}^1	R ²	R ³	\mathbb{R}^4	Ar
1	E ₁	A ₁	B_1	C1	D_1	_	Н	Н	Н	Ме	Ph
2	E ₂	1		C_2	D_1		Η	Н	Н	Et	Ph
3	Ē ₃			$\tilde{C_2}$	D_2		Η	Н	Н	Et	4-FPh
4	E ₄			$\tilde{C_2}$	$\tilde{D_3}$		Η	Н	Н	Et	4-ClPh
5	E ₅			$\begin{array}{c} C_2\\ C_2\\ \end{array}$	D_4		Η	Η	Н	Et	4-BrPh
6	E ₆			$\overline{C_2}$	D_5	_	Η	Η	Η	Et	4-MePh
7	E ₇			C ₂	D_6		Η	Η	Η	Et	4-OMePh
8	E ₈			$\tilde{C_2}$	D_7	_	Η	Н	Н	Et	3-OMePh
9	Eo			$\tilde{C_3}$	D_1		Н	Н	Н	i-Pr	Ph
10	E10			$\tilde{C_4}$	D_1		Н	Н	Н	n-Bu	Ph
11	E ₁₁	A_2	B_2	C_2	D_1	_	Cl	н	н	Et	Ph
12	E ₁₂	2	- 2	C ₂	D_2^{-1}		Cl	Н	Н	Et	4-FPh
13	E ₁₃			\tilde{C}_2	D_3^2		Cl	Н	Н	Et	4-ClPh
14	E_{14}			\tilde{C}_2	D_{4}	_	Cl	Н	Н	Et	4-BrPh
15	E ₁₅			C_2	D_5		Cl	Н	Н	Et	4-MePh
16	E ₁₅ E ₁₆			C_2	D_6		Cl	Н	Н	Et	4-OMePh
17				C_2 C_2	-		Cl	Н	Н	Et	3-OMePh
	E ₁₇		D		D ₇	_			н Н	Et	Ph
18	E18	A_3	B_3	C_2	D_1		\mathbf{Br}	Η	п	Ľt	гш

55

(B₅): $R^1 = H$, $R^2 = OMe$, $R^3 = H = 60$


(B₆): $R^1 = H$, $R^2 = H$, $R^3 = OMe$

7 TABLE 1-continued

Ex	Target	Reactants				Substituted groups of compound (E) or (F)					
No.	compound	А	В	С	D	Е	\mathbb{R}^1	\mathbb{R}^2	R ³	\mathbb{R}^4	Ar
19	E19			C ₂	D_2	_	Br	Н	Н	Et	4-FPh
20	E ₂₀			$\tilde{C_2}$	D_3		Br	Н	Н	Et	4-ClPh
21	E_{21}^{-2}			$\tilde{C_2}$	$\tilde{D_4}$		Br	Η	Н	Et	4-BrPh
22	E ₂₂			$\tilde{C_2}$	D_5		\mathbf{Br}	Н	Н	Et	4-MePh
23	E23			C_2	D_6		\mathbf{Br}	Н	Н	Et	4-OMePh
24	E ₂₄			C_2	D_7		\mathbf{Br}	Н	Н	Et	3-OMePh
25	E ₂₅	A_4	B_4	C_2	D_1	_	Η	OBn	Н	Et	Ph
26	E ₂₆	A_5	B_5	$\tilde{C_2}$	D_1		Н	OMe	Н	Et	Ph
27	E ₂₇	A ₆	B ₆	$\tilde{C_2}$	D_1	_	Η	Н	OMe	Et	Ph
28	F	\mathbf{A}_{1}	B ₁	C1	D_1	E_1	Н	Н	Н	Me	Ph
29	F_2	A_1	B_1	c_2	D_1	E_2	Н	Н	Н	Et	Ph
30	F_3	A	B_1	C ₃	D_1	E ₉	Н	Н	Н	i-Pr	Ph
31	F_4	A	B	C_4	D_1	E ₁₀	Н	Н	Н	n-Bu	Ph
32	F ₅	A_2	B_2	C_2	D_1	E11	Cl	Н	Н	Et	Ph
33	F_6	A_3	B_3	C_2	D_1	E ₁₈		Н	Н	Et	Ph
34	F ₇	A_4	B_4	C_2	D_1	E ₂₅	Н	OBn	Н	Et	Ph
35	F ₈	A_5	B_5	$\tilde{C_2}$	D_1^{-1}	E ₂₆		OMe	Н	Et	Ph
36	F ₉	A ₆	B_6	\tilde{C}_2	D_1^{-1}	E ₂₇		Н	OMe	Et	Ph

Preparation of 3-cyanochromene $(B_1) \sim (B_6)$

Each of the compounds $(B_1) \sim (B_6)$ was prepared according to scheme I below by: mixing 20.0 mmol of a corresponding one of salicylaldehydes $(A_1) \sim (A_6)$ with 30.0 mmol of acrylonitrile to form a mixture; slowly adding a DABCO aqueous solution containing 22.0 mmol of DABCO and 30 mL, of 30 water into the mixture to obtain a reaction solution; followed by refluxing the reaction solution under a nitrogen gas environment for 24 hrs.



The reaction product thus formed in the reaction solution was extracted using CH_2Cl_2 , and was subsequently dried, filtered, concentrated, and purified by column chromatography with a ⁶⁵ suitable eluent so as to obtain a colorless crystal of 3-cyano-chomene of formula (B).

Structure identification of 3-cyanochromenes $[(B_1) \sim (B_6)]$

3-Cyano-2H-chromene (B₁): (2.51 g, 80%); m.p.: 44-45°
C.; R_f=0.75 (ethyl acetate:n-hexane=1:6); IR (KBr cm⁻¹): 3059, 2851, 2212, 1623, 1482, 1458, 1233, 1211, 1148, 1034, 1020, 898, 759; ¹H-NMR (400 MHz, CDCl₃) δ/ppm: 4.81 (2H, d, J=1.6 Hz, H-2), 6.87 (1H, d, 8.0 Hz, ArH), 6.97 (1H, td, J=7.6, 1.2 Hz, ArH), 7.10 (1H, dd, J=8.0, 1.2 Hz, ArH), 7.17 (1H, br s, H-4), 7.27 (1H, m, ArH); ¹³C-NMR (100 MHz, CDCl₃) δ/ppm: 64.2, 103.3, 116.4, 116.5, 120.0, 122.4, 128.4, 132.7, 138.8, 154.3; MS (EI) m/z: 157 (M⁺, 92%), 156 (100%).

6-Chloro-3-cyano-2H-chromene (B₂): (2.99 g, 78%); m.p.: 124-126° C.; R_j=0.76 (ethyl acetate:n-hexane=1:6); IR (KBr cm⁻¹): 3064, 2917, 2213, 1629, 1479, 1239, 1212, 1019, 914, 816; ¹H-NMR (400 MHz, CDCl₃) δ/ppm: 4.83 (2H, d, J=1.6 Hz, H-2), 6.82 (1H, d, J=8.6 Hz, H-8), 7.09 (1H, d, J=2.4 Hz, H-5), 7.11 (1H, br s, H-4), 7.22 (1H, dd, J=8.6, 2.4 Hz, H-7); ¹³C-NMR (100 MHz, CDCl₃) δ/ppm: 64.4, 104.8, 115.9, 118.0, 121.1, 127.3, 127.7, 132.3, 137.6, 152.7; MS (EI) m/z: 193 ([M+2]⁺, 29%), 191 (M⁺, 91%), 190 (87%), 156 (100%).

6-Bromo-3-cyano-2H-chromene (B₃): (3.54 g, 75%); m.p.: 132-133° C.; R_j=0.77 (ethyl acetate:n-hexane=1:6); IR (KBr cm⁻¹): 3063, 2878, 2211, 1627, 1476, 1236, 1211, 1018, 915, 815; ¹H-NMR (400 MHz, CDCl₃) δ /ppm: 4.83 (2H, d, J=1.2 Hz, H-2), 6.76 (1H, d, J=8.4 Hz, H-8), 7.10 (1H, br s, H-4), 7.23 (1H, d, J=2.4 Hz, H-5), 7.36 (1H, dd, J=8.4, 2.4 Hz, H-7); ¹³C-NMR (100 MHz, CDCl₃) δ /ppm: 64.4, 104.7, 114.4, 115.9, 118.4, 121.5, 130.6, 135.1, 137.4, 153.2; MS (EI) m/z: 237 ([M+2]⁺, 41%), 235 (M⁺, 49%), 157 (75%), 156 (100%).

7-Benzyloxy-3-cyano-2H-chromene (B₄): (3.79 g, 72%); m.p.: 108-109° C.; R_f=0.35 (ethyl acetate:n-hexane=1:9); IR (KBr cm⁻¹): 3033, 2957, 2206, 1615, 1561, 1271, 1166, 851, 737; ¹H-NMR (400 MHz, CDCl₃) δ /ppm: 4.77 (2H, d, J=1.2 Hz, H-2), 5.05 (2H, s, OCH₂Ph), 6.49 (1H, d, J=2.4 Hz, H-8), 6.59, dd, J=8.6, 2.4 Hz, H-6), 7.01 (1H, d, J=8.6 Hz, H-5), 7.12 (1H, m, H-4), 7.32-7.41 (5H, m, ArH); ¹³C-NMR (100 MHz, CDCl₃) δ /ppm: 64.4, 70.2, 99.5, 102.8, 109.6, 113.6, 116.9, 127.4, 128.2, 128.7, 129.6, 136.0, 138.7, 155.9, 162.5; MS (EI) m/z: 263 (M⁺, 7%), 91 (100%); Anal. calcd for C₁₇H₁₃NO₂ (263.29): C, (77.55); H, (4.98); N, (5.32). found. C, (77.57); H, (5.02); N, (5.20).


7-Methoxy-3-cyano-2H-chromene (B₅): (2.77 g, 74%); m.p.: 97-99° C.; R_f=0.30 (ethyl acetate:n-hexane=1:9); IR (KBr cm⁻¹): 3065, 2964, 2205, 1618, 1564, 1435, 1279, 868, ⁵ 805; ¹H-NMR (400 MHz, CDCl₃) δ/ppm: 3.78 (3H, s, OCH₂), 4.76 (2H, d, J=0.8 Hz, H-2), 6.40 (1H, d, J=2.4 Hz, H-8), 6.50, (1H, J=8.4, 2.4 Hz, H-6), 7.00 (1H d, J=8.4 Hz, H-5), 7.11 (1H, br s, H-4); ¹³C-NMR (100 MHz, CDCl₃) 10 δ/ppm: 55.5, 64.4, 99.3, 101.8, 108.9, 113.4, 116.9, 129.5, 138.7, 155.9, 163.4; MS (EI) m/z: 187 (M⁺, 80%), 186 (100%).

8-Methoxy-3-cyano-2H-chromene (B₆): (2.85 g, 76%); m.p.: 105-106° C.; $R_f=0.58$ (ethyl acetate:n-hexane=1:3); IR 15 (KBr cm⁻¹): 3056, 2956, 2838, 2210, 1625, 1606, 1575, 1482, 1336, 1274, 1221, 1098, 1021, 733; ¹H-NMR (400 MHz, CDCl₃) 8/ppm: 3.88 (3H, s, OCH₃), 4.87 (2H, d, J=1.2 Hz, H-2), 6.75 (1H, dd, J=5.6, 3.6 Hz, ArH), 6.93, (1H, J=3.6 Hz, ArH), 6.93 (1H, d, J=5.6 Hz, ArH), 7.18 (1H, t, J=1.2 Hz, 20 1451, 1403, 1225, 1180, 1115, 1058, 761, 705; EI-MS (70 H-4); ¹³C-NMR (100 MHz, CDCl₃) δ/ppm: 56.1, 64.5, 103.4, 115.2, 116.3, 120.2, 120.7, 122.2, 138.8, 143.2, 148.0; MS (EI) m/z: 187 (M⁺, 100%), 186 (39%), 144 (69%), 116 (40%), 89 (32%). 25

Examples 1~27

Preparation of the Chromene Compounds $(E_1) \sim (E_{27})$

Each of the chromene compounds (E_1) ~ (E_{27}) of Examples 1~27 was prepared according to scheme II below by: dissolving 5.0 mmol of a corresponding one of 3-cyanochromenes (B_1) ~ (B_6) in THF to form a solution; mixing 7.5 mmol of a corresponding one of the compounds (C_1) - (C_4) and 10.0 35 mmol of a corresponding one of the compounds $(D_1) \sim (D_7)$ with the above solution to form a reaction solution; followed by refluxing the reaction solution under a nitrogen gas environment for 1~3 hrs.




Scheme II

(B) $(B_1): R^1 = H, R^2 = H, R^3 = H$ (B₂): $R^1 = C1$, $R^2 = H$, $R^3 = H$ (B₃): $R^1 = Br$, $R^2 = H$, $R^3 = H$ (B₄): $R^1 = H$, $R^2 = OBn$, $R^3 = H$ (B₅): $R^1 = H$, $R^2 = OMe$, $R^3 = H$ (B₆): $R^1 = H$, $R^2 = H$, $R^3 = OMe$

$$\frac{\text{R}^{2}\text{ONa} + \text{ArNH}_{2}}{\text{(C)}}$$

$$\frac{\text{(C)}}{\text{THF, reflux 1-3 h}}$$

 (D_1) : Ar = Ph $(C_1): R^4 = Me$ (D₂): Ar = 4-FPh (C₂): $R^4 = Et$ $(D_3): Ar = 4-C1Ph$ (C₃): $R^4 = i - Pr$ (D_4) : Ar = 4-BrPh $(C_4): R^4 = n-Bu$ (D_5) : Ar = 4-MePh (D_6) : Ar = 4-OMePh



The reaction product thus formed was separated from the reaction solution, and was then purified by column chromatography with a suitable eluent so as to obtain a vellow crystal of intermediate chromene compound of formula (E).

> Structure Identification of the Intermediate Chromene Compounds $[(E_1) \sim (E_{27})]$

3-Methoxymethyl-2-phenylimino-2H-chromene (E.): (0.86 g, 65%); m.p.: 64-65° C.; R_e=0.512 (ethyl acetate:nhexane=1:7); ¹H-NMR (CDCl₃, 400 MHz) δ/ppm: 3.53 (s, 3H, CH₂OCH₃), 4.40 (d, J=1.6 Hz, 2H, CH₂OCH₃), 7.00 (H, J=8.0 Hz, 1H, ArH), 7.06-7.12 (m, 2H, RC=NArH), 1.17 (dt, J=6.4, 1.2 Hz, 2H, RC=NArH), 7.25 (td, J=7.2, 1.6 Hz, 1H, ArH), 7.29 (dd, 7.6, 1.6 Hz, 1H, ArH) 7.32-7.36 (m, 3H, ArH, ArCH=C, RC=NArH); ¹³C-NMR (CDCl₃, 100 MHz) δ/ppm: 58.98, 69.57, 115.33, 119.79, 122.87, 123.58, 123.69, 127.10, 128.54, 128.90, 129.63, 129.68, 145.95, 147.74, 152.23; IR (KBr cm⁻¹): 2936, 2869, 2363, 1644, 1585, 1487, eV) m/z: 265 (M⁺, 10%), 251 (18%), 250 (100%), 235 (27%), 234 (21%), 233 (11%), 232 (22%), 222 (21%); Anal. calcd for C₁₇H₁₅NO₂: N, 5.28; C, 76.96; H, 5.70. found: N, 5.22; C, 76.93; H, 5.68.

3-Ethoxymethyl-2-phenylimino-2H-chromene (E_2) : (1.1 g, 79%); m.p.: 71~72° C.; R=0.564 (ethyl acetate:n-hexane=1:7); ¹H-NMR (CDCl₃, 400 MHz) δ/ppm: 1.37 (t, J=6.8 Hz, 3H, CH₂OCH₂CH₃), 3.74 (q, J=6.8 Hz, 2H, CH₂OCH₂CH₃), 4.53 (d, J=2.0 Hz, 2H, CH₂OCH₂CH₃), 7.04 (dd, J=8.0, 0.4 Hz, 1H, ArH), 7.11-7.16 (m, 2H, RC=NArH), 7.21-7.24 (m, 2H, RC=NArH), 7.29 (td, J=8.0, 1.2 Hz, 1H, ArH), 7.34-7.41 (m, 3H, ArH, RC=NArH), 7.42 (t, J=1.6 Hz, 1H, ArCH==C); ¹³C-NMR (CDCl₃, 100 MHz) δ/ppm: 15.58, 67.06, 67.84, 115.69, 120.22, 123.21, 123.92, 124.02, 127.46, 128.90, 129.62, 129.93, 130.02, 146.36, 148.22, 152.57; IR (KBr cm⁻¹): 2978, 2861, 2362, 1640, 1583, 1486, 1449, 1386, 1227, 1182, 1116, 1064, 758, 703; EI-MS (70 eV) m/z: 279 (M⁺, 0.3%), 251 (17%), 250 (100%), 236 (49%), 235 (58%), 233 (47%), 231 (17%), 221 (12%); Anal. 40 calcd for C₁₈H₁₇NO₂: N, 5.01; C, 77.40; H, 6.13. found: N, 4.82; C, 77.46; H, 6.21.

3-Ethoxymethyl-2-(4-fluorophenyl)imino-2H-chromene (E₃): (0.94 g, 63%); m.p.; 84~86° C., R_f=0.538 (ethyl acetate: n-hexane=1:7); ¹H-NMR (CDCl₃, 400 MHz) δ/ppm: 1.35 (t, 45 J=7.2 Hz, 3H, CH₂OCH₂CH₃), 3.72 (q, J=6.8 Hz, 2H, CH₂OCH₂CH₃), 4.49 (d, J=1.6 Hz, 2H, CH₂OCH₂CH₃), 7.02 (dd, J=8.0, 0.8 Hz, 1H, ArH), 7.04-7.07 (m, 2H, RC=NArH), 7.13 (td, J=7.6, 1.2 Hz, 1H, ArH), 7.18-7.22 (m, 2H, RC=NArH), 7.30 (td, 7.6, 1.6 Hz, 1H, ArH), 7.34 (td, J=7.6, 50 1.2 Hz, 1H, ArH), 7.40 (t, J=1.2 Hz, 1H, ArCH=C); ¹³C-NMR (CDCl₃, 100 MHz) δ/ppm: 15.23, 66.74, 67.47, 115.07, 115.30, 119.89, 123.72, 124.40, 124.47, 127.20, 129.24, 129.67, 129.77, 152.16, 158.21, 160.62; IR (KBr cm⁻¹): 2975, 2861, 2365, 1642, 1589, 1502, 1227, 1185, 1155, 1111, 1063, 844, 758; EI-MS (70 eV) m/z: 299 ([M+2]⁺, 0.06%), 297 (M⁺, 0.3%), 269 (17%), 268 (100%), 255 (17%), 254 (30%), 253 (71%), 252 (16%), 251 (32%), 240 (20%); Anal. calcd for C₁₈H₁₆FNO₂: N, 4.71; C, 72.71; H, 5.42. found: N, 4.70; C, 72.77; H, 5.45.

3-Ethoxymethyl-2-(4-chlorophenyl)imino-2H-chromene (E_4) : (1.00 g, 64%); m.p.: 84~86° C., $R_f=0.564$ (ethyl acetate: n-hexane=1:7); ¹H-NMR (CDCl₃, 400 MHz) δ/ppm: 1.35 (t, J=6.8 Hz, 3H, CH₂OCH₂CH₃), 3.71 (q, J=6.8 Hz, 2H, CH₂OCH₂CH₃), 4.49 (d, J=1.6 Hz, 2H, CH₂OCH₂CH₃), 7.03 (d, J=8.4 Hz, 1H, ArH), 7.12-7.16 (m, 2H, RC=NArH), 7.20 (dd, J=6.8, 1.6 Hz, 1H, ArH), 7.26-7.33 (m, 2H, RC=NArH), 7.35 (dd, J=7.6, 1.2 Hz, 1H, ArH), 7.38 (d, J=8.0 Hz, 1H, ArH), 7.42 (t, J=1.6 Hz, 1H, ArCH=C); ¹³C-NMR (CDCl₃, 100 MHz) δ /ppm: 15.23, 66.75, 67.42, 115.30, 119.83, 123.79, 124.35, 127.30, 128.60, 128.78, 129.10, 129.77, 130.10, 144.59, 152.11, 162.89; IR (KBr cm⁻¹): 2971, 2859, 2361, 1641, 1593, 1483, 1448, 1224, 1182, 1117, 1057, 837, 5 760; EI-MS (70 eV) m/z: 315 ([M+2]+, 0.2%), 313 (M+, 0.9%), 286 (34%), 285 (23%), 284 (100%), 271 (31%), 270 (29%), 269 (94%), 268 (50%), 256 (20%), 207 (22%); Anal. calcd for C₁₈H₁₆ClNO₂: N, 4.46; C, 68.90; H, 5.14. found: N, 4.31; C, 68.91; H, 5.30.

3-Ethoxymethyl-2-(4-bromophenyl)imino-2H-chromene (E₅): (1.16 g, 65%); m.p.: 73~74° C.; Rf=0.590 (ethyl acetate: n-hexane=1:7); ¹H-NMR (CDCl₃, 400 MHz) δ/ppm: 1.34 (t, J=7.2 Hz, 3H, CH₂OCH₂CH₃), 3.71 (q, J=7.2 Hz, 2H, CH₂OCH₂CH₃), 4.48 (d, J=2.0 Hz, 2H, CH₂OCH₂CH₃), 7.04 15 (d, J=8.4 Hz, 1H, ArH), 7.08 (dt, J=8.8, 2.8 Hz, 2H, RC=NArH), 7.15 (td, J=7.6, 1.2 Hz, 1H, ArH), 7.31 (td, J=8.0, 1.6 Hz, 1H, ArH), 7.36 (dd, J==7.6, 1.6 Hz, 1H, ArH), 7.43 (t, J=2.0 Hz, 1H, ArCH=C), 7.45 (td, J=8.8, 2.4 Hz, 1H, RC=NArH); ¹³C-NMR (CDCl₃, 100 MHz) δ/ppm: 15.25, 20 (CH₃)₂), 4.50 (d, J=2.0 Hz, 2H, CH₂OCH(CH₃)₂), 7.01 (d, 66.79, 67.43, 115.36, 116.60, 119.86, 123.86, 124.76, 127.28, 129.10, 129.85, 130.25, 131.59, 145.11, 148.50, 152.14; IR (KBr cm⁻¹): 2973, 2878, 2369, 1637, 1597, 1477, 1218, 1177, 1108, 1061, 1005, 835, 758; EI-MS (70 eV) 359 $([M+2]^+, 0.35\%), 357 (M^+, 0.26\%), 330 (73\%), 328 (68\%), 25$ 315 (79%), 314 (63%), 313 (62), 233 (81%), 231 (100%), 220 (66%); Anal. calcd for C₁₈H₁₆BrNO₂: N, 3.91; C, 60.35; H, 4.50. found: N, 3.81; C, 60.37; H, 4.51.

3-Ethoxymethyl-2-(4-ethylphenyl)imino-2H-chromene (E₆): (0.98 g, 67%); m.p.: 104~105° C.; $R_{f}=0.564$ (ethyl 30 acetate:n-hexane=1:7) ¹H-NMR (CDCl₃, 400 MHz) δ/ppm: 1.37 (t, J=7.2 Hz, 3H, CH₂OCH₂CH₃), 2.39 (s, 3H, RC==NArCH₃) 3.74 (q, J=6.8 Hz, 2H, CH₂OCH₂CH₃), 53 (d, J=1.6 Hz, 2H, CH₂OCH₂CH₃), 7.06 (d, J=8.0 Hz, 1H, ArH), 7.13 (td, J=7.6, 1.2 Hz, 1H, ArH) 7.16-7.21 (m, 4H, 35 hexane=1:7); ¹H-NMR (CDCl₃, 400 MHz) δ/ppm: 1.00 (t, RC=NArH), 7.29 (td, J=8.0, 1.6 Hz, 1H, ArH), 7.32 dd, J=7.6, 1.6 Hz, 1H, ArH), 7.39 (t, J=1.6 Hz 1H, ArCH=C); ¹³C-NMR (CDCl₃, 100 MHz) δ/ppm: 15.58, 21.30, 67.04, 67.88, 115.64, 120.28, 123.31, 123.85, 127.42, 129.50, 129.66, 129.79, 129.84, 133.55, 143.56, 147.96, 152.63; IR 40 (KBr cm⁻¹): 2971, 2870, 2361, 1651, 1589, 1477, 1415, 1382, 1228, 1178, 1122, 1061, 902, 809, 766, 736, 691; EI-MS (70 eV) m/z: 293 (M⁺, 0.6%), 265 (19%), 264 (100%), 245 (87%), 249 (21%), 248 (49%), 246 (16%), 236 (10%); Anal. calcd for C₁₈H₁₆CH₃NO₂: N, 4.77; C, 77.79; H, 6.53. 45 found: N, 4.67; C, 77.80; H, 6.51.

3-Ethoxymethyl-2-(4-methoxyphenyl)imino-2Hchromene (E₇): (1.00 g, 65%); m.p.: 78~79° C., R_f=0.385 (ethyl acetate:n-hexane=1:7); ¹H-NMR (CDCl₃, 400 MHz) δ/ppm: 1.35 (t, J=7.2 Hz, CH₂OCH₂CH₃), 3.72 (q, J=6.8 Hz, 50 2H, CH₂OCH₂CH₃), 3.83 (s, 3H, RC=NArOCH₃), 4.50 (d, J=1.6 Hz, 2H, CH₂OCH₂CH₃), 6.91 (dt, J=9.2, 3.2 Hz, 2H, RC=NArH), 7.07 (d, J=8.0 Hz, 1H, ArH), 7.11 (td, J=7.6, 1.2 Hz, 1H, ArH), 7.28 (dt, J=9.2, 3.2 Hz, 2H, RC=NArH), 7.31-7.34 (m, 2H, ArH), 7.35 (t, J=1.6 Hz, 1H, ArCH=C); 55 ¹³C-NMR (CDCl₃, 100 MHz) δ/ppm: 15.56, 55.64, 67.01, 67.89, 114.08, 115.57, 120.33, 123.84, 127.96, 127.40, 129.34, 129.79, 129.90, 139.12, 147.57, 152.61, 156.52; IR (KBr cm⁻¹): 2969, 2866, 2363, 1648, 1599, 1507, 1446, 1244, 1178, 1113, 1061, 1032, 832, 745; EI-MS (70 eV) m/z: 60 309 (M⁺, 5%), 281(150), 280 (75%), 266 (25%), 265 (100%), 264 (15%), 262 (16%), 250 (22%); Anal. calcd for C₁₉H₁₉NO₃: N, 4.53; C, 73.77; H, 6.19. found: N, 4.44; C, 73.78; H, 6.23.

3-Ethoxymethyl-2-(3-methoxyphenyl)imino-2Hchromene (E₈): (0.97 g, 63%); R_f=0.410 (ethyl acetate:nhexane=1:7); ¹H-NMR (CDCl₃, 400 MHz) δ/ppm: 1.34 (t,

65

J=6.8 Hz, 3H, CH₂OCH₂CH₃), 3.71 (q, J=6.8 Hz, 2H, CH₂OCH₂CH₂), 3.82 (s, 3H, RC=NArOCH₂), 4.50 (d, J=1.6 Hz, 2H, CH₂OCH₂CH₃), 6.68 (dt, J=8.4, 0.8 Hz, 1H, RC=NArH), 6.75 (t, J=2.0 Hz, 1H, RC=NArH), 6.79 (dt, J=8.0, 0.8 Hz, 1H, RC=NArH), 7.04 (d, J=8.4 Hz, 1H, ArH), 7.12 (td, J=7.6, 1.2 Hz, 1H, ArH), 7.25 (t, J=8.0 Hz, 1H, RC=NArH), 7.29 (td, J=8.0, 1.6 Hz, 1H, ArH), 7.34 (dd, J=7.6, 1.6 Hz, 1H, ArH), 7.40 (t, J=1.6 Hz, 1H, ArCH=C); ¹³C-NMR (CDCl₃, 100 MHz) ð/ppm: 15.24, 55.18, 66.76, 10 67.51, 108.31, 109.71, 115.33, 115.43, 119.90, 123.66, 127.18, 129.25, 129.67, 129.85, 147.36, 152.29, 159.99; EI-MS (70 eV) m/z: 309 (M⁺, 0.5%), 281 (16%), 280 (83%), 266 (31%), 265 (100%), 264 (41%), 263 (22%), 262 (18%); HRMS (ESI, m/z): Calcd. for C₁₉H₁₉NO₃: 309.3591; found: 309.3590.

3-isopropoxymethyl-2-phenylimino-2H-chromene (E_{0}) : (1.2.0 q, 82%); m.p.: 107~108° C., R_f=0.605 (ethyl acetate: n-hexane=1:7); ¹H-NMR (CDCl₃, 400 MHz) δ/ppm: 1.30 (d, J=6.0 Hz, 6H, CH₂OCH(CH₃)₂), 3.77-3.84 (m, 1H, CH₂OCH J=8.0 Hz, 1H, ArH), 7.08-7.13 (m, 2H, RC=NArH), 7.19 (dt, J=6.4, 0.8 Hz, 2H, RC=NArH), 7.27 (td, J=7.6, 1.6 Hz, 1H, ArH), 7.32-7.37 (m, 3H, ArH, RC=NArH), 7.41 (t, J=1.6, 1H, ArCH=C); ¹³C-NMR (CDCl₃, 100 MHz) δ/ppm: 22.24, 65.25, 72.25, 115.37, 120.00, 122.87, 123.59, 123.67, 127.15, 128.60, 129.54, 12974, 129.83, 146.12, 148.03, 152.25; IR (KBr cm⁻¹): 2964, 2873, 2364, 1647, 1590, 1484, 1451, 1370, 1216, 1179, 1124, 1039, 763, 691; EI-MS (70 eV) m/z: 293 (M⁺, 0.7%), 251 (19%), 250 (100%), 236 (16%), 235 (85%), 234 (64%), 233 (20%), 232 (23%), 222 (23%); Anal. calcd for C₁₉H₁₉NO₂: N, 4.77; C, 77.79; H, 6.53. found: N, 4.68; C, 77.87; H, 6.57.

3-Butoxymethyl-2-phenylimino-2H-chromene (E_{10}) : (1.32 g, 86%); m.p.: 86~88° C.; R_f=0.651 (ethyl acetate:n-J=7.2 Hz, 3H, CH₂OCH₂CH₂CH₂CH₂CH₃), 1.44-1.54 (m, 2H, CH₂OCH₂CH₂CH₂CH₂CH₃), 1.68-1.75 2H. (m, CH₂OCH₂CH₂CH₂CH₃), 3.58 (t, J=6.4 Hz, 2H. CH₂OCH₂CH₂CH₂CH₃), 4.51 (d, J=2.0 Hz, 2H, CH₂O(CH₂) ₃CH₃), 7.04 (d, J=8.4 Hz, 1H, ArH), 7.10-7.15 (m, 2H, RC=NArH), 7.21 (dt, J=6.8, 1.6 Hz, 2H, RC=NArH), 7.29 (td, J=8.0, 1.6 Hz, 1H, ArH), 7.34-7.39 (m, 3H, ArH, RC=NArH), 7.40 (t, J=1.6, 1H, ArCH=C); ¹³C-NMR (CDCl₃, 100 MHz) δ/ppm: 13.95, 19.40, 31.84, 67.71, 71.23, 115.39, 119.95, 122.88, 123.60, 123.69, 127.16, 128.59, 129.45, 129.60, 129.68, 146.09, 147.92, 152.29; IR (KBr cm^{-1}): 2955, 2864, 2367, 1646, 1590, 1482, 1450, 1381, 1216, 1180, 1113, 1071, 759, 689; EI-MS (70 eV) m/z: 307 (M⁺, 0.5%), 251 (18%), 250 (100%), 237 (16%), 235 (84%), 234 (72%), 233 (16%), 232 (21%), 222 (16%); Anal. calcd for C₂₀H₂₁NO₂: N, 4.56; C, 78.15; H, 6.89. found: N, 4.46; C, 78.14; H, 6.87.

6-Chloro-3-ethoxymethyl-2-phenylimino-2H-chromene (E₁₁): (1.06 g, 68%); m.p.: 58~59° C., $R_f=0.465$ (ethyl acetate:n-hexane=1:7); ¹H-NMR (CDCl₃, 400 MHz) δ/ppm: 1.33 (t, J=6.8 Hz, 3H, CH₂OCH₂CH₃), 3.70 (q, J=6.8 Hz, 2H, CH₂OCH₂CH₃), 4.49 (d, J=1.6 Hz, 2H, CH₂OCH₂CH₃), 6.95 (d, J=8.8 Hz, 1H, ArH), 7.11 (tt, J=7.6, 0.8 Hz, 1H, RC=NArH), 7.13 (dt, J=7.6, 1.2 Hz, 2H, RC=NArH), 7.22 (dd, J=8.8, 2.8 Hz, 1H, ArH), 7.31-7.38 (m, 4H, ArH, ArCH=C, RC=NArH); ¹³C-NMR (CDCl₃, 100 MHz) δ/ppm: 15.24, 66.83, 67.43, 116.14, 121.19, 122.81, 123.97, 126.48, 128.43, 128.64, 129.39, 130.80, 145.68, 147.17, 150.70; IR (KBr cm⁻¹): 2972, 2871, 2358, 1651, 1590, 1479, 1418, 1382, 1226, 1178, 1121, 1060, 902, 810, 766, 736, 690; ET-MS (70 eV) m/z: 315 ([M+2]⁺, 0.5%), 313 (M⁺, 0.4%), 286 (34%), 285 (23%), 284 (100%) 271 (79%), 270 (37%), 269 (53%), 268 (39%); Anal. calcd for $\rm C_{18}H_{16}CINO_2:$ N, 4.46; C, 68.90; H, 5.14. found: N, 4.37; C, 68.89; H, 5.13.

6-Chloro-3-ethoxymethyl-2-(4-fluorophenyl)imino-2Hchromene (E₁₂): (1.06 g, 64%); m.p.: 36-137° C., R_f=0.419 (ethyl acetate:n-hexane=1:7); ¹H-NMR (CDCl₃, 400 MHz) 5 δ/ppm: 1.33 (t, J=7.2 Hz, 3H, CH₂OCH₂CH₃), 3.70 (g, J=7.2 Hz, 2H, CH₂OCH₂CH₃), 4.47 (d, J=2.0 Hz, 2H, CH₂OCH₂CH₃), 6.98 (d, J=8.8 Hz, 1H, ArH) 7.01-7.05 (m, 2H, RC=NArH), 7.16-7.19 (m, 2H, RC=NArH), 7.25 (dd, J=8.8, 2.4 Hz, 1H, ArH), 7.32 (t, J=2.0 Hz, 1H, ArCH=C), 10 7.33 (d, J=2.4 Hz, 1H, ArH); ¹³C-NMR (CDCl₃, 100 MHz) δ/ppm: 15.23, 66.86, 67.41, 1145.18, 115.40, 116.68, 121.20, 124.40, 124.48, 126.58, 128.56, 129.48, 130.78, 150.63, 158.40, 160.81; IR (KBr cm⁻¹): 2970, 2866, 2367, 1653, 1500, 1419, 1182, 1120, 1064, 907, 816; ET-MS (70 eV) m/z: 15 333 [M+2]⁺, 0.05%), 331 (M⁺, 0.5%), 304 (31%), 303 (20%), 302 (91%), 290 (24%), 288 (100%), 286 (45%), 274 (14%); Anal. calcd for C₁₈H₁₅ClFNO₂: N, 4.22; C, 65.16; H, 4.56. found: N, 4.15; C, 65.18; H, 4.66.

6-Chloro-3-ethoxymethyl-2-(4-chlorophenyl)imino-2Hchromene (E₁₃): (1.15 g, 66%); m.p.: 126~128° C., R=0.488 (ethyl acetate:n-hexane=1:7); ¹H-NMR (CDCl₃, 400 MHz) δ/ppm: 1.33 (t, J=7.6 Hz, 3H, CH₂OCH₂CH₃), 3.70 (q, J=6.8 Hz, 2H, CH₂OCH₂CH₃), 4.47 (d, J=2.0 Hz, 2H, CH₂OCH₂CH₃), 6.98 (d, J=8.8 Hz, 1H, ArH), 7.11 (dt, J=9.6, 25 2.8 Hz, 2H, RC=NArH), 7.24-7.27 (m, 2H, RC=NArH), 7.30 (dd, J=8.8, 2.4 Hz, 1H, ArH), 7.32 (d, J=2.4 Hz, 1H, ArH), 7.33 (t, J=1.6 Hz, 1H, ArCH=C); ¹³C-NMR (CDCl₃, 100 MHz) 8/ppm: 15.22, 66.87, 67.36, 116.71, 117.94, 121.15, 124.29, 126.61, 128.71, 128.89, 129.58, 130.64, 30 130.92, 136.68, 150.60, 159.83; IR (KBr cm⁻¹): 2972, 2866, 2366, 1647, 1480, 1418, 1258, 1181, 1121, 1063, 1004, 892, 812; EI-MS (70 eV) m/z: 349 ([M+2]+, 0.14%), 347 (M+, 0.4%) 320 (70%), 319 (100%), 306 (59%), 305 (53%), 304 (91%), 302 (47%), 207 (37%); Anal. calcd for 35 C₁₈H₁₅Cl₂NO₂: N, 4.02; C, 62.08; H, 4.34. found: N, 4.01; C, 62.11; H, 38.

6-Chloro-3-ethoxymethyl-2-(4-bromophenyl)imino-2Hchromene (E₁₄): (1.23 g, 63%); m.p.: 119~121° C.; R_f=0.465 (ethyl acetate:n-hexane=1:7); ¹H-NMR (CDCl₃, 400 MHz) 40 δ/ppm: 1.33 (t, J=6.8 Hz, 3H, CH₂OCH₂CH₃), 3.70 (q, J=6.8 Hz, 2H, CH₂OCH₂CH₃), 4.46 (d, J=2.0 Hz, 2H, CH₂OCH₂CH₃), 6.97 (d, J=8.8 Hz, 1H, ArH), 7.05 (dt, J=8.8, 2.0 Hz, 2H, RC=NArH), 7.25 (dd, J=8.4, 2.4 Hz, 1H, ArH), 7.33-7.34 (m, 2H, ArH, ArCH=C), 7.45 (dt, J=8.4, 2.0 Hz, 45 2H, RC=NArH); ¹³C-NMR (CDCl₃, 100 MHz) δ/ppm: 15.23, 66.87, 67.34, 116.70, 116.89, 121.14, 124.68, 126.60, 128.92, 129.58, 130.63, 131.66, 144.78, 147.69, 150.58; IR (KBr cm⁻¹): 2970, 2866, 2367, 1647, 1590, 1500, 1470, 1418, 1381, 1230, 1179, 1118, 1060, 900, 80; EI-MS (70 eV) 50 m/z: 393 ([M+2]+, 0.14%), 391 (M+, 0.19%), 366 (26%), 364 (100%), 362 (75%), 350 (32%), 349 (94%), 348 (69%), 347 (80%); Anal. calcd for $C_{18}H_{15}BrClNO_2$: N, 3.57; C, 55.06; H, 3.85. found: N, 3.49; C, 55.08; H, 3.89.

6-Chloro-3-ethoxymethyl-2-(4-methylphenyl)imino-2H-55 chromene (E_{15}): (1.10 g, 67%); m.p.: 76~77° C., R_{f} =465 (ethyl acetate:n-hexane=1:7); ¹H-NMR (CDCl₃, 400 MHz) δ /ppm: 1.33 (t, J=7.2 Hz, 3H, CH₂OCH₂CH₃), 2.35 (s, 3H, RC=NArCH₃), 3.70 (q, J=7.2 Hz, 2H, CH₂OCH₂CH₃), 4.48 (d, J=1.6 Hz, 2H, CH₂OCH₂CH₃), 6.97 (d, J=8.8 Hz, 1H, 60 ArH), 7.10-7.16 (m, 4H, RC=NArH), 7.22 (dd, J=8.8, 2.4 Hz 1H, ArH), 7.29 (t, J=2.0 Hz, 1H, ArCH=C), 7.30 (d, J=2.0 Hz, 1H, ArCH); ¹³C-NMR (CDCl₃, 100 MHz) δ /ppm: 15.24, 21.00, 66.82, 67.49, 116.70, 121.28, 122.94, 126.46, 128.13, 128.59, 129.24, 129.30, 130.98, 133.61, 142.87, 146.94, 65 150.78; IR (KBr cm⁻¹): 2963, 2858, 2367, 1644, 1478, 1414, 1381, 1265, 1220, 1181, 1122, 1064, 900, 810; EI-MS (70

eV) m/z: 329 ([M+2]⁺, 0.48%), 327 (M⁺, 0.72%), 300 (33%), 299 (22%) 298 (100%), 286 (30%), 285 (67%), 284 (98%), 282 (55%); Anal. calcd for $C_{19}H_{18}CINO_2$: N, 4.27; C, 69.62; H, 5.53. found: N, 4.25; C, 69.58; H, 5.54.

6-Chloro-3-ethoxymethyl-2-(4-methoxyphenyl)imino-2H-chromene (E16): (1.10 q, 64%); m.p.: 136~138° C., $R_{f}=0.302$ (ethyl acetate:n hexane=1:7); ¹H-NMR (CDCl₃, 400 MHz) δ/ppm: 1.33 (t, J=7.2 Hz, 3H, CH₂OCH₂CH₃), 3.70 (q, J=6.8 Hz, 2H, CH₂OCH₂CH₃), 3.83 (s, 3H, RC=NArOCH₃), 4.48 (d, J=1.6 Hz, 2H, CH₂OCH₂CH₃), 6.90 (dt, 8.8, 2.4 Hz, 2H, RC=NArH), 7.01 (d, J=8.4 Hz, ArH), 7.22-7.26 (m, 3H, ArH, RC=NArH), 7.27 (t, J=2.0 Hz, 1H, ArCH=C), 7.31 (d, J=2.4 Hz, 1H, ArH); ¹³C-NMR (CDCl₃, 100 MHz) δ /ppm: 15.25, 55.42, 66.82, 67.53, 113.87, 116.65, 121.38, 124.71, 126.47, 127.82, 128.60, 129.27, 131.13, 138.45, 146.55, 150.80, 156.48; IR (KBr cm⁻¹): 2977, 2861, 2365, 1643, 1597, 1507, 1418, 1242, 1179, 1133, 1062, 1023, 816; EI-MS (70 eV) m/z: 345 ([M+ 2]+, 3%), 343 (M+, 9%), 316 (34%), 315 (23%), 314 (96%), 20 302 (35%), 300 (49%), 299 (100%), 298 (34%), 284 (23%); Anal. calcd for C₁₉H₁₈ClNO₃: N, 4.07; C, 66.38; H, 5.28. found: N, 4.02; C, 66.33; H, 5.27.

6-Chloro-3-ethoxymethyl-2-(3-methoxyphenyl)imino-2H-chromene (E17): (1.13 g, 66%); m.p.: 96.5~97.5° C., R=0.326 (ethyl acetate:n-hexane=1:1); ¹H-NMR (CDCl₃, 400 MHz) δ/ppm: 1.34 (t, J=7.2 Hz, 3H, CH₂OCH₂CH₃), 3.71 (q, J=7.2 Hz, 2H, CH₂OCH₂CH₃), 3.82 (s, 3H, RC=NArOCH₃), 4.49 (d, J=1.6 Hz, 2H, CH₂OCH₂CH₃), 6.69 (dt, J=8.4, 0.8 Hz, 1H, RC=NArH), 6.74 (t, J=2.0 Hz, 1H, RC=NArH), 6.78 (dt, J=8.0, 0.8 Hz, 1H, RC=NArH), 6.98 (d, J=8.4 Hz, 1H, ArH), 7.21 (dd, J=8.0, 2.4 Hz, 1H, ArH) 7.25 (t, J=8.0 Hz, 1H, RC=NArH), 7.31 (m, 2H, ArCH=C, ArH); ¹³C-NMR (CDCl₃, 100 MHz) δ /ppm: 15.20, 55.16, 66.79, 67.38, 108.33, 109.80, 115.20, 116.73, 121.12, 126.46, 128.51, 129.27, 129.36, 130.72, 146.94, 150.67, 159.98; IR (KBr cm⁻¹): 2970, 2862, 2364, 1650, 1584, 1480, 1268, 1231, 1180, 1123, 1065, 908, 853, 807, 781; EI-MS (70 eV) m/z: 345 ([M+2]+, 0.7%), 343 (M+, 0.24%), 316 (18%), 314 (55%), 302 (13%), 301.5 (16%), 300 (100%), 298 (33%), 297 (15%), 296 (15%); Anal. calcd for C₁₉H₁₈ClNO₃: N, 4.07; C, 66.38; H, 5.28. found: N, 4.00; C, 66.40; H, 5.26.

6-Bromo-3-ethoxymethyl-2-phenylimino-2H-chromene (E_{18}) : (1.16 g, 64%) m.p.: 78~80° C., R_f=0.452 (ethyl acetate: n-hexane=1:7); ¹H-NMR (CDCl₃, 400 MHz) δ/ppm: 1.33 (t, J=6.8 Hz, 3H, CH₂OCH₂CH₃), 3.70 (q, J=7.2, Hz, 2H, CH₂OCH₂CH₃), 4.49 (d, J=2.0 Hz, 2H, CH₂OCH₂CH₃), 6.90 (d, J=8.8 Hz, 1H, ArH), 7.08 (tt, J=8.8, 0.8 Hz, 1H, RC=NArH), 7.17 (dt, J=8.4, 2.4 Hz, 2H, RC=NArH), 7.30 (t, J=2.0, 1H, ArCH=C) 7.32-7.37 (m, 3H, ArH, RC=NArH), 7.46 (d, J=2.4 Hz, 1H, ArH); ¹³C-NMR (CDCl₃, 100 MHz) δ /ppm: 15.23, 66.82, 67.42, 115.99, 117.09, 121.69, 122.81, 123.98, 128.33, 128.64, 129.47, 130.79, 132.24, 145.62, 147.09, 151.19; IR (KBr cm⁻¹): 2971, 2870, 2361, 1651, 1589, 1415, 1382, 1228, 1178, 1122, 1061, 902, 809, 766, 736, 691; EI-MS (70 eV) m/z: 359 ([M+2]⁺, 1.4%), 357 (M⁺, 1.4%), 330 (98%), 329 (100%), 316 (79%), 315 (68%), 314 (90%), 312 (55%); Anal. calcd for C₁₈H₁₆BrNO₂: N, 3.91; C, 60.35; H, 4.50. found: N, 3.68; C, 60.19; H, 4.78.

 J=1.6, 1H, ArCH=C), 7.39 (dd, J=8.8, 2.4 Hz, 1H, ArH), 7.47 (d, J=2.4 Hz, 1H, ArH); 13 C-NMR (CDCl₃, 100 MHz) δ /ppm: 15.23, 66.84, 67.40, 115.17, 115.40, 116.14, 117.02, 121.70, 124.40, 128.39, 129.55, 130.77, 132.31, 151.11, 158.39, 160.80; IR (KBr cm⁻¹): 2972, 2866, 2363, 1650, ⁵ 1591, 1499, 1414, 1383, 1183, 1122, 1062, 908, 818, 781; EI-MS (70 eV) m/z: 377 ([M+2]⁺, 0.14%), 375 (M⁺, 0.03%), 348 (63%), 347 (60%), 334 (86%), 332 (100%), 238 (64%), 237 (49%); Anal. calcd for C₁₈H₁₅BrFNO₂: N, 3.72; C, 57.46; H, 4.02. found: N, 3.65; C, 57.56; H, 4.05.

6-Bromo-3-ethoxymethyl-2-(4-chlorophenyl)imino-2Hchromene (E₂₀): (1.27 g, 62%); m.p.: 144~145° C., R_f=0.476 (ethyl acetate:n-hexane=1:7); ¹H-NMR (CDCl₃, 400 MHz) δ/ppm: 1.33 (t, J=6.8 Hz, 3H, CH₂OCH₂CH₃), 3.70 (q, J=6.8 Hz, 2H, CH₂OCH₂CH₃), 4.47 (d, J=2.0 Hz, 2H, CH₂OCH₂CH₃), 6.92 (d, J=8.8 Hz, 1H, ArH) 7.11 (dt, J=8.8, 3.2 Hz, 2H, RC=NArH), 7.30 (dt, J==8.8, 2.8 Hz, 2H, RC=NArH), 7.33 (t, J=2.0, 1H, ArCH=C), 7.39 (dt, J=8.8, 2.4 Hz, 1H, ArH), 7.48 (d, J=2.0 Hz, 1H, ArH); ¹³C-NMR 20 (CDCl₃, 100 MHz) δ/ppm: 15.22, 66.86, 67.34, 116.23, 117.05, 121.64, 124.29, 128.71, 128.74, 129.13, 129.58, 130.64, 132.42, 144.22, 147.61, 151.07; IR (KBr cm⁻¹): 2971, 2863, 2361, 1646, 1599, 1477, 1382, 1225, 1180, 1122, 1063, 904, 811; EI-MS (70 eV) m/z: 393 ([M+2]⁺, 0.02%), 391 (M⁺, 0.02%), 364 (100%), 363 (81%), 351 (35%), 350 ²⁵ (90%), 349 (60%), 348 (73%), 346 (33%); Anal. calcd for C₁₈H₁₅BrClNO₂: N, 3.57; C, 55.06; H, 3.85. found: N, 3.51; C, 55.00; H, 3.95.

6-Bromo-3-ethoxymethyl-2-(4-bromophenyl)imino-2Hchromene (E_{21}): (1.35 g, 62%); m.p.: 129~431° C., $R_f=0.500_{-30}$ (ethyl acetate:n-hexane=1:7); ¹H-NMR (CDCl₃, 400 MHz) δ/ppm: 1.33 (t, J=7.2 Hz, 3H, CH₂OCH₂CH₃), 3.70 (q, J=6.8 Hz, 2H, $CH_2OCH_2CH_3$), 4.47 (d, J=1.6 Hz, 2H, CH₂OCH₂CH₃), 6.92 (dd, J=8.8, 2.0 Hz, 1H, ArH), 7.05 (dt, J=8.4, 3.2 Hz, 2H, RC=NArH), 7.34 (t, J=1.6 Hz, 1H, 35 ArCH=C), 7.40 (dd, J=8.8, 2.4, 1H, ArH), 7.44-7.51 (m, 2H, RC=NArH), 7.55 (dd, J=9.2, 2.0 Hz, 1H, ArH); ¹³C-NMR (CDCl₃, 100 MHz) δ/ppm: 15.22, 66.87, 67.33, 116.27, 117.07, 121.63, 124.69, 128.86, 129.60, 130.59, 131.70, 132.47, 132.60, 144.68, 147.67, 151.05; IR (KBr cm⁻¹): 2971, 2866, 2362, 1644, 1476, 1382, 1180, 1122, 1064, 903, 827; EI-MS (70 eV) m/z: 438 ([M+2]+, 0.31%), 434 (M+ 0.01%), 408 (61%), 396 (47%), 394 (96%), 392 (66%), 312 (100%), 311 (51%), 310 (58%); Anal. calcd for C₁₈H₁₅Br₂NO₂: N, 3.46; C, 49.46; H, 3.46. found: N, 3.15; C, 15 48.40; H, 3.40.

6-Bromo-3-ethoxymethyl-2-(4-methylphenyl)imino-2Hchromene (E₂₂): (1.22 g, 66%); m.p.: 116~117° C., R_f=0.500 (ethyl acetate:n-hexane=1:7); ¹H-NMR (CDCl₃, 400 MHz) δ/ppm: 1.32 (t, J=7.2 Hz, 3H, CH₂OCH₂CH₃), 2.35 (s, 3H, RC=NArCH₃), 3.69 (q, J=6.8 Hz, 2H, CH₂OCH₂CH₃), 4.48 50 (d, J=1.6 Hz, 2H, CH₂OCH₂CH₃), 6.91 (d, J=8.8 Hz, 1H, ArH), 7.10-716 (m, 4H, RC=NArH) 7.27 (t, J=1.6 Hz, 1H, ArCH=C), 7.36 (dd, J=8.8, 2.4 Hz, 1H, ArH), 7.44 (d, J=2.0 Hz, 1H, ArH); ¹³C-NMR (CDCl₃, 100 MHz) δ/ppm: 15.23, 20.99, 66.79, 67.46, 76.68, 117.04, 121.77, 122.94, 127.96, ₅₅ 129.23, 129.42, 130.96, 132.14, 133.60, 142.83, 146.79, 151.24; IR (KBr cm⁻¹) 2971, 2874, 2362, 1652, 1592, 1507, 1222, 1182, 1120, 1063, 908, 814; EI-MS (70 eV) m/z: 373 ([M+2]⁺, 1.3%), 371 (M⁺, 1.3%), 344 (87%), 343 (87%), 330 (87%), 329 (45%), 328 (100%), 32% (36%), 326 (29%); Anal. calcd for $C_{19}H_{18}BrNO_7$: N, 3.76; C, 61.30; H, 4.87. ⁶⁰ found: N, 3.74; C, 61.18; H, 4.83.

6-Bromo-3-ethoxymethyl-2-(4-methoxyphenyl)imino-2H-chromene (E_{23}): (1.30 g, 67%); m.p.: 134~135° C., R_{f} =0.309 (ethyl acetate:n-hexane=1:7); ¹H-NMR (CDCl₃, 400 MHz) δ/ppm: 1.32 (t, J=6.8 Hz, CH₂OCH₂CH₃), 3.69 (q, 65 J=7.2 Hz, 2H, CH₂OCH₂CH₃), 3.82 (s, 3H, RC=NArOCH₃), 4.47 (d, J=2.0 Hz, 2H, CH₂OCH₂CH₃),

6.89 (dt, J=7.2, 2.0 Hz, 2H, RC—NArH), 6.94 (d, J=8.4 Hz, 1H, ArH), 7.22-7.26 (m, 3H, RC—NArH, ArCH—C), 7.37 (dd, J=8.4, 2.4 Hz, 1H ArH), 7.45 (d, J=2.0 Hz, 1H, ArH); ¹³C-NMR (CDCl₃, 100 MHz) δ /pm: 15.24, 55.40, 66.79, 67.50 113.84, 115.91, 116.99, 121.87, 124.72, 127.65, 129.43, 131.12, 132.10, 138.40, 146.39, 151.26, 156.46; IR (KBr cm⁻¹): 2976, 2869, 2365, 1642, 1593, 1505, 1413, 1382, 1241, 1178, 1126, 1060, 1025, 815; EI-MS (70 eV) m/z: 389 ([M+2]⁺, 0.5%), 387 (M⁺, 0.8%), 360 (33%), 358 (36%), 345 (60%), 344 (37%), 343 (100%), 331 (24%), 328 (27%); Anal. calcd for C₁₉H₁₈BrNO₃: N, 3.61; C, 58.78; H, 4.67. found: N, 3.61; C, 58.70; H, 4.65.

6-Bromo-3-ethoxymethyl-2-(3-methoxyphenyl)imino-2H-chromene (E₂₄): (1.23 g, 65%); m.p.: 93~94° C., R_f=0.35 7 (ethyl acetate:n-hexane=1:7); ¹H-NMR (CDCl₃, 400 MHz) δ/ppm: 1.33 (t, J=6.8 Hz, 3H, CH₂OCH₂CH₃), 3.70 (q, J=7.2 Hz, 2H, CH₂OCH₂CH₃), 3.81 (s, 3H, RC=NArOCH₃), 4.84 (d, J=1.6 Hz, 2H, CH₂OCH₂CH₃), 6.68 (dt, J=8.4, 0.8 Hz, 1H, RC=NArH), 6.72 (t, J=2.0 Hz, 1H, RC=NArH), 6.77 (dt, J=8.0, 0.8 Hz, 1H, RC=NArH), 6.92 (d, J=8.8 Hz, 1H, ArH), 7.25 (t, J=8.0 Hz, 1H, RC=NArH), 7.31 (t, J=1.6 Hz, 1H, ArCH=C), 7.37 (dd, J=8.8, 2.4 Hz 1H ArH), 7.47 (d, J=2.4 Hz 1H ArH); ¹³C-NMR (CDCl₃, 100 MHz) δ /ppm: 15.22, 55.20, 66, 82, 67.39, 108.32, 109.85, 115.19, 116.03, 117.14, 121.66, 128.345, 129.48, 130.72, 132.27, 146.93, 151.19, 160.00; IR (KBr cm⁻¹): 2970, 2361, 1648, 1584, 1477, 1268, 1232, 1182, 1121, 1065, 904, 807, 783; EI-MS $\begin{array}{l} (70 \ eV) \ m/z: \ 389 \ ([M+2]^+, \ 0.4\%), \ 387 \ (M^+, \ 0.6\%), \ 360 \\ (44\%), \ 359 \ (11\%), \ 358.5 \ (44\%), \ 346 \ (62\%), \ 345 \ (47\%), \ 344 \end{array}$ (100%), 342 (25%); Anal. calcd for C₁₉H₁₈BrNO₃: N, 3.61; C, 58.78; H, 4.67. found: N, 3.61; C, 58.80; H, 4.70.

7-Benzyloxy-3-ethoxymethyl-(Z)-2-phenylimino-2Hchromene (E₂₅): (1.19 g, 62%); m.p.: 94-95° C., R_f=0.40 (ethyl acetate:n-hexane=1:9); IR (KBr cm⁻¹): 2973, 2867, 1649, 1612, 1505, 1385, 1262, 1164, 1130, 1065, 695; ¹H-NMR (400 MHz, CDCl₃) δ/ppm: 1.32 (3H, t, J=6.8 Hz, OCH₂CH₃), 3.70 (2H, q, J=6.8, Hz, OCH₂CH₃), 4.48 (2H, d, J=1.6 Hz, CH₂OCH₂CH₃), 4.99 (2H, s, OCH₂Ph), 6.64 (1H, d, J=2.4 Hz, H-8), 6.76 (1H, dd, J=8.4, 2.4 Hz, H-6), 7.10 (1H, t, J=7.6 Hz, ArH), 7.17 (2H, d, J=7.6 Hz, ArH), 7.22 (1H, d, J=8.4 Hz, H-5), 7.30-7.39 (8H, m, H-4 and ArH); $^{13}\text{C-NMR}$ (100 MHz, CDCl₃) δ/ppm: 15.3, 66.7, 67.5, 70.2, 101.2, 111.6, 113.6, 122.8, 123.5, 126.2, 127.5, 127.9, 128.1, 128.6, 128.6, 129.9, 136.1, 146.3, 148.1, 153.6, 160.3; MS (EI): 385 (M⁺, 0.2%), 250 (42%), 91 (100%); Anal. calcd for C₂₅H₂₃NO₃ (385.46): C, 77.90; H, 6.01; N, 3.63. found: C, 77.94; H, 6.00; N, 3.60.

7-Methoxy-3-ethoxymethyl-(Z)-2-phenylimino-2H-chromene (E_{26}): (0.87 g, 57%); mp 107-108° C., R_f =0.40 (ethyl acetate:n-hexane=1:9); IR (KBr cm⁻¹): 2973, 2868, 1649, 1610, 1508, 1486, 1445, 1389, 1264, 1159, 1131, 1064, 759; ¹H-NMR (400 MHz, CDCl₃) δ /ppm: 1.33 (3H, t, J=6.8 Hz, OCH₂CH₃), 3.71 (2H, q, J=6.8, Hz, OCH₂CH₃), 3.77 (3H, OCH₃), 4.48 (2H, d, J=1.6 Hz, CH₂OCH₂CH₃), 6.55 (1H, J=2.4 Hz, H-8), 6.69 (1H, dd, J=8.4, 2.4, H-6), 7.10 (1H, tt, J=7.6, 1.2 Hz, ArH), 7.16-7.19 (2H, m, ArH), 7.23 (1H, d, J=8.4 Hz, H-4); ¹³C-NMR (100 MHz, CDCl₃) δ /ppm: 15.3, 55.6, 66.7, 67.5, 100.1, 111.1, 113.3, 122.8, 123.5, 126.0, 127.9, 128.6, 129.9, 146.3, 148.2, 153.7, 161.2; MS (EI): 309 (M⁺, 0.5%), 280 (100%) 265 (94%), 264 (72%), 252 (60%); Anal. calcd for C₁₉H₁₉NO₃ (309.36): C, 73.77; H, 6.19; N, 4.53. found: C, 73.87, H, 6.09; N, 11.46.


8-Methoxy-3-ethoxymethyl-(Z)-2-phenylimino-2Hchromene (E_{27}): (1.04 g, 67%); m.p.: 88-90° C., R_{f} =0.43 (ethyl acetate:n-hexane=1:9); IR (KBr cm⁻¹): 2972, 2866, 1645, 1586, 1482, 1269, 1224, 1183, 1106, 1062, 765; ¹H-NMR (400 MHz, CDCl₃) δ /ppm: 1.34 (3H, t, J=6.8 Hz, OCH₂CH₃), 3.72 (2H, q, J=6.8, Hz, OCH₂CH₃), 3.81 (3H, s, OCH₃), 4.52 (2H, d, J=1.6 Hz, CH₂OCH₂CH₃), 6.90 and 6.95 (each 1H, dd, J=8.0, 1.6 Hz, H-5 and H-7), 7.05 (1H, t, J=8.0 Hz, H-6), 7.11 (1H, tt, J=7.2, 1.2 Hz, ArH), 7.33-7.37 (2H, m, ArH), 7.37 (1H, t, J=1.6 Hz, H-4), 7.41-7.44 (2H, m, ArH); 13 C-NMR (100 MHz, CDCl₃) δ /ppm: 15.3, 56.6, 66.8, 67.6, 113.1, 119.2, 120.7, 123.4, 124.0, 124.1, 128.5, 129.6, 129.7, 5142.1, 145.5, 146.9, 147.4; MS (EI): 309 (M⁺, 0.5%), 280 (100%), 265 (95%), 264 (70%); Anal. calcd. For Cl₁₉H₁₉NO₃ (309.36): C, 73.77; H, 6.19; N, 4.53. found: C, 73.79; H, 6.21; N, 4.50.

Examples 28-36


Preparation of the Coumarin Compounds $[(F_1)\sim(F_9)]$

Each of the coumarin compounds (F_1) ~ (F_9) was prepared ¹⁵ according to scheme III below by: dissolving 1.0 mmol of a corresponding one of the chromene compounds $(E_1)(E_2)(E_9)$ $(E_{10})(E_{11})(E_{18})(E_{25})(E_{26})$ and (E_{27}) into 10 mL of THF to form a coumarin solution, and adding 5 mL, 15 wt % of HCl aqueous solution into the coumarin solution at 0° C. to form ²⁰ a reaction solution, followed by raising the reaction solution from 0° C. to room temperature under a nitrogen gas for 30 mins.

Scheme III



 $\begin{array}{l} (E_1); R^1 = H, R^2 = H, R^3 = H, R^4 = Me, Ar = Ph \\ (E_2); R^1 = H, R^2 = H, R^3 = H, R^4 = Et, Ar = Ph \\ (E_9); R^1 = H, R^2 = H, R^3 = H, R^4 = i\text{-}Pr, Ar = Ph \\ (E_{10}); R^1 = H, R^2 = H, R^3 = H, R^4 = n\text{-}Bu, Ar = Ph \\ (E_{11}); R^1 = Cl, R^2 = H, R^3 = H, R^4 = Et, Ar = Ph \\ (E_{18}); R^1 = Br, R^2 = H, R^3 = H, R^4 = Et, Ar = Ph \\ (E_{25}); R^1 = H, R^2 = OBn, R^3 = H, R^4 = Et, Ar = Ph \\ (E_{26}); R^1 = H, R^2 = OMe, R^3 = H, R^4 = Et, Ar = Ph \\ (E_{27}); R^1 = H, R^2 = H, R^3 = OMe, R^4 = Et, Ar = Ph \end{array}$



$$\begin{split} (F_1): & R^1 = H, \, R^2 = H, \, R^3 = H, \, R^4 = Me, \, Ar = Ph \\ (F_2): & R^1 = H, \, R^2 = H, \, R^3 = H, \, R^4 = Et, \, Ar = Ph \\ (F_3): & R^1 = H, \, R^2 = H, \, R^3 = H, \, R^4 = i \text{-} Pr, \, Ar = Ph \\ (F_4): & R^1 = H, \, R^2 = H, \, R^3 = H, \, R^4 = n\text{-} Bu, \, Ar = Ph \\ (F_5): & R^1 = Cl, \, R^2 = H, \, R^3 = H, \, R^4 = Et, \, Ar = Ph \\ (F_6): & R^1 = Br, \, R^2 = H, \, R^3 = H, \, R^4 = Et, \, Ar = Ph \\ (F_7): & R^1 = H, \, R^2 = OBn, \, R^3 = H, \, R^4 = Et, \, Ar = Ph \\ (F_8): & R^1 = H, \, R^2 = OMe, \, R^3 = H, \, R^4 = Et, \, Ar = Ph \\ (F_9): & R^1 = H, \, R^2 = H, \, R^3 = OMe, \, R^4 = Et, \, Ar = Ph \\ (F_9): & R^1 = H, \, R^2 = H, \, R^3 = OMe, \, R^4 = Et, \, Ar = Ph \end{split}$$

The reaction solution was mixed with a saturated NaCl aque-65 ous solution after the reaction was completed. The reaction product in the reaction solution was subsequently extracted

using CH_2Cl_2 , and was cleaned with a saturated NaHCO₃ aqueous solution, dried, filtered, and concentrated, so as to obtain a colorless crystal of a coumarin compound of formula (F).

Structure Identification of the Coumarin Compounds $[(F_1)\sim(F_9)]$

3-Methoxymethylcoumarin (F₁): (0.13 g, 68); m.p.: 10 72-73° C., R_f=0.33 (ethyl acetate:n-hexane=1.5)); IR (KBr cm⁻¹): 2957, 2919, 1713, 1603, 1454, 1394, 1168, 1115, 1043, 1010, 925, 780, 630; ¹H-NMR (400 MHz, CDCl₃) δ/ppm: 3.52 (3H, s, CH₂OCH₃), 4.41 (2H, d, J=1.6 Hz, CH₂OCH₃), 7.28 (1H, td, J=7.6, 0.8 Hz, ArH), 7.34 (1H, d, 15 J=8.4 Hz, ArH), 7.48-7.53 (2H, m, ArH), 7.78 (1H, t, J=1.6 Hz, H-4); ¹³C-NMR (100 MHz, CDCl₃) δ/ppm: 59.1, 69.0, 116.5, 119.2, 124.5, 126.0, 127.7, 131.1, 138.2, 153.1, 160.4; MS (EI) m/z: 190 (M⁺, 2%), 175 (68%), 160 (100%), 103 (41%); Anal. calcd for C₁₁H₁₀O₃ (190.20): C, 69.46; H, 5.30. 20 found: C, 69.21; H, 5.42.

3-Ethoxymethylcoumarin (F₂): (0.15 g, 73%); m.p.: 95-96° C., R_f=0.38 (ethyl acetate:n-Hexane=1:5); IR (KBr cm⁻¹): 2970, 2924, 2863, 2341, 1717, 1605, 1574, 1447, 1384, 1283, 1172, 1116, 1061, 919, 756, 630; ¹H-NMR (400
MHz, CDCl₃) δ/ppm: 1.31 (3H, t, J=7.0 Hz, OCH₂CH₃), 3.68 (2H, q, J=7.0 Hz, OCH₂CH₃), 4.46 (2H, d, J=1.6 Hz, CH₂OCH₂CH₃), 7.28 (1H, td, J=7.6, 1.2 Hz, ArH), 7.34 (1H, d, J=8.0 Hz, ArH), 7.48-7.52 (2H, ArH), 7.81 (1H, t, J=1.6 Hz, H-4); ¹³C-NMR (100 MHz, CDCl₃) δ/ppm: 15.2, 66.9, 66.9, 30 116.5, 119.2, 124.4, 126.4, 127.7, 131.0, 138.1, 153.1, 160.5; MS (EI) m/z: 175 ([M-(C₂H₅)]⁺, 53%), 160 (100%), 132 (51%), 131 (42%); Anal. calcd for C₁₂H₁₂O₃ (204.22): C, 70.57; H, 5.92. found: C, 70.60; H, 5.95.
3-Isopropoxymethylcoumarin (F₃): (0.16 g, 73%);

35 R₂=0.46 (ethyl acetate:n-hexane=1:5), m.p.: 72-71° C., IR (KBr cm⁻¹): 2970, 1715, 1602, 1449, 1169, 1125, 1036, 917, 754, 630; ¹H-NMR (400 MHz, CDCl₃) δ/ppm: 1.27 (6H, d, J=6.4 Hz, OCH(CH₃)₂), 3.78 (1H, hept, J=6.4 Hz, OCH (CH₃)₂), 4.45 (2H, d, J=1.6 Hz, CH₂OCH(CH₃)₂), 7.27 (1H,

40 td, J=7.6, 0.8 Hz, ArH), 7.33 (1H, d, J=8.0 Hz, ArH), 7.47-7.52 (2H, m, ArH), 7.82 (1H, t, J=1.6 Hz, H-4); ¹³C-NMR (100 MHz, CDCl₃) δ /ppm: 22.1, 64.5, 72.4, 116.5, 119.3, 124.4, 127.0, 127.7, 130.9, 137.9, 153.0, 160.5; MS (EI) m/z: 175 ([M-(C₃H₇)]⁺, 52%), 160 (100%), 159 (49%), 132 45 (45%); Anal. calcd for C₁₃H₁₄O₃ (218.25): C, 71.54; H, 6.47. found: C, 71.51; H, 6.45.

3-Butoxymethylcoumarin (F_{4}): (0.18 g, 77%); m.p.: 69-70° C., R_f=0.49, (ethyl acetate:n-hexane=1:5); IR (KBr cm⁻¹): 2924, 2854, 1717, 1637, 1456, 1385, 1282, 1170, ⁵⁰ 1144, 1114, 1055, 1018, 919, 756, 631; ¹H-NMR (400 MHz, CDCl₃) δ /ppm: 0.96 (3H, t, J=7.4 Hz, OCH₂CH₂CH₂CH₃), 1.40-1.49 (2H, m, OCH₂CH₂CH₂CH₃), 1.63-1.70 (2H, m, $OCH_2CH_2CH_2CH_3$, 3.61 (2H, t. J=6.6 Hz. OCH₂CH₂CH₂CH₃CH₃), 4.45 (2H, d, J=1.6 Hz, CH₂OC₄H₉), 55 7.28 (1H, td, J=7.2, 0.8 Hz, ArH), 7.34 (1H, H, J=8.0 Hz, ArH), 7.47-7.52 (2H, m, ArH), 7.79 (1H, br s, H-4); ¹³C-NMR (100 MHz, CDCl₃) 8/ppm: 13.9, 19.3, 31.7, 67.1, 71.3, 116.5, 119.3, 124.4, 126.5, 127.7, 131.0, 138.0, 153.0, 160.5; MS (EI) m/z: 175 ([M-(C₄H₉)]⁺, 37%), 160 (100%), 132 60 (53%); Anal. calcd for $C_{14}H_{16}O_3$ (232.28): C, 72.39; H, 6.94. found: C, 72.35; H, 6.95.

6-Chloro-3-ethoxymethylcoumarin (F_5): (0.18 g, 75%); R_j=0.45 (ethyl acetate:n-hexane=1:5), m.p.: 100-101° C.; IR (KBr cm⁻¹); 2972, 2861, 1729, 1637, 1605, 1570, 1478, 1379, 1266, 1172, 1124, 1055, 1014, 925, 826, 758, 659; ¹H-NMR (400 MHz, CDCl₃) δ /ppm: 1.31 (3H, t, J=7.0 Hz, OCH₂CH₃), 3.68 (2H, q, J=7.0 Hz, OCH₂CH₃), 4.45 (2H, d, $\begin{array}{l} J{=}1.6~{\rm Hz}, {\rm CH_2OCH_2CH_3}), 7.28~(1{\rm H}, {\rm d}, J{=}8.8~{\rm Hz}, {\rm H{\text -}8}), 7.45\\ (2{\rm H}, {\rm dd}, J{=}8.8, 2.4~{\rm Hz}, {\rm H{\text -}7}), 7.50~(1{\rm H}, {\rm d}, J{=}2.4~{\rm Hz}, {\rm H{\text -}5}), 7.74\\ (1{\rm H}, {\rm brs}, {\rm H{\text -}4}); {}^{13}{\rm C{\text -}NMR}~(100~{\rm MHz}, {\rm CDCI_3})~\delta/{\rm ppm:}~15.1,\\ 66.8, 66.9, 117.9, 120.3, 126.9, 127.9, 129.7, 130.9, 136.7,\\ 151.4, 159.8; {\rm MS}~({\rm EI})~{\rm m/z:}~211~([({\rm M{\text +}2){\text -}({\rm C_2}{\rm H_5})]^{+}, 14\%), 209~5\\ ([{\rm M{\text -}({\rm C_2}{\rm H})]^{+}, 45\%), 194~(100\%), 166~(54\%), 165~(41\%);\\ {\rm Anal.~calcd~for~C_{12}{\rm H_{11}ClO_3}~(238.67):~{\rm C},~60.39;~{\rm H},~4.65.\\ {\rm found:~C},~60.21;~{\rm H},~4.64. \end{array}$

6-Bromo-3-ethoxymethylcoumarin (F_6): (0.20 g, 71%); m.p.: 118-119° C., R_f=0.48 (ethyl acetate:n-hexane=1:5); IR 10 (KBr cm⁻¹): 2970, 2860, 1728, 1637, 1601, 1476, 1379, 1266, 1246, 1173, 1125, 1054, 1013, 923, 824, 759, 650; ¹H-NMR (400 MHz, CDCl₃) δ/ppm: 1.31 (3H, t, J=7.0 Hz, OCH₂CH₃), 3.67 (2H, q, J=7.0 Hz, OCH₂CH₃), 4.45 (2H, d, J=1.6 Hz, CH₂OCH₂CH), 7.22 (1H, d, J=8.8 Hz, H-8), 7.58 15 (1H, dd, J=8.8, 2.4 Hz, H-7), 7.65 (1H, d, J=2.4 Hz, H-5), 7.73 (1H, t, J=1.6 Hz, H-4); ¹³C-NMR (100 MHz, CDCl₃) δ/ppm: 15.1, 66.8, 66.9, 117.0, 118.3, 120.8, 127.8, 130.0, 133.7, 136.6, 151.9, 159.8; MS (EI) m/z: 255 ([(M+2)-(C₂H₅)]⁺ 34%), 253 ([M-(C₂H₅)]⁺, 39%), 240 (95%), 239 (22%), 238 20 (100%), 212 (36%), 211 (33%), 210 (36%), 102 (63%); Anal. calcd for C₁₂H₁₁BrO₃ (283.12): C, 50.91; H, 3.92. found: C, 50.82; H, 3.92.

7-Benzyloxy-3-ethoxymethylcoumarin (F_7) : (0.27 g, 87%); m.p.: 122-124° C., R_7 =0.48 (ethyl acetate:n-hexane=1: 25 6); IR (KBr cm⁻¹): 2976, 2923, 2858, 1714, 1620, 1388, 1245, 1163, 1132, 843, 724; ¹H-NMR (400 MHz, CDCl₃) δ /ppm: 1.30 (3H, t, J=6.8 Hz, OCH₂CH₃), 3.66 (2H, q, J=6.8 Hz, OCH₂CH₃), 4.42 (2H, d, J=1.2 Hz, CH₂OCH₂CH₃), 5.11 (2H, s, OCH₂Ph), 6.88 (1H, d, J=2.4 Hz, H-8), 6.92 (1H, dd, 30 J=8.8, 2.4 Hz, H-6), 7.33-7.45 (6H, m, H-5 and ArH), 7.73 (1H, br s, H-4); ¹³C-NMR (100 MHz, CDCl₃) δ /ppm: 15.1, 66.7, 66.9, 70.4, 101.6, 113.0, 113.2, 122.8, 127.5, 128.3, 128.6, 128.7, 135.8, 138.5, 154.7, 160.8, 161.3; MS (EI) m/z: 310 (M⁺, 0.4%), 91 (100%); Anal. calcd. for C₁₉H₁₉O₄ 35 (310.34): C, 73.53; H, 5.85. found: C, 73.49; H, 5.87.

7-Methoxy-3-ethoxymethyl-coumarin (F₈): (0.19 g, 81%); m.p.: 64-66° C., R_f=0.58 (ethyl acetate:n-hexane=1:3); IR (KBr cm⁻¹): 2975, 2909, 2874, 1726, 1624, 1390, 1151, 1121, 1022, 926, 823; ¹H-NMR (400 MHz, CDCl₃) δ /ppm: 40 1.30 (3H, t, J=6.8 Hz, OCH₂CH₃), 3.67 (2H, q, J=6.8 Hz, OCH₂CH₃), 3.87 (3H, s, OCH₃), 4.43 (2H, d, J=1.6 Hz, CH₂OCH₂CH₃), 6.83 (1H, d, J=2.8 Hz, H-8), 6.85 (1H, dd, J=8.4, 2.8 Hz, H-6), 7.40 (1H, d, J=8.4 Hz, H-5) 7.74 (1H, t, J=1.6 Hz, H-4); ¹³C-NMR (100 MHz, CDCl₃) δ /ppm: 15.2, 45 55.7, 66.7, 67.0, 100.5, 112.6, 112.9, 122.7, 128.6, 138.6, 154.8, 160.9, 162.2; MS (EI) m/z: 234 (M⁺, 1%), 205 ([M-(C₂H₅)]⁺, 30%), 190 (100%), 162 (69%); Anal. calcd. for C₁₃H₁₄O₄ (234.25): C, 66.66; H, 6.02. found: C, 66.54; H, 6.00. 50


8-Methoxy-3-ethoxymethyl-coumarin (F₉): (0.20 g, 85%); m.p.: 131-133° C., R_f=0.51 (ethyl acetate:n-hexane=1:3); IR (KBr cm⁻¹): 2974, 2862, 1698, 1607, 1580, 1481, 1456, 1279, 1268, 1177, 1124, 1103, 1066, 914, 744; ¹H-NMR (400 MHz, CDCl₃) δ /ppm: 1.31 (3H, t, J=6.8 Hz, OCH₂CH₃), 3.68 55 (2H, q, J=6.8 Hz, OCH₂CH₃), 3.97 (3H, s, OCH₃), 4.46 (2H, d, J=1.6 Hz, CH₂OCH₂CH₃), 7.05 and 7.09 (each 1H, dd, J=8.0, 1.2 Hz, H-5 and H-7), 7.21 (1H, t, J=8.0 Hz, H-6), 7.78 (1H, J=1.6 Hz, H-4); ¹³C-NMR (CDCl₃, 100 MHz) δ /ppm: 15.1, 56.2, 66.9, 112.9, 119.2, 119.9, 124.3, 126.7, 138.1,

142.7, 147.1, 159.9; MS (EI) m/z: 234 (M⁺, 0.3%), 205 ([M-(C₂H₅)]⁺, 31%), 190 (100%), 162 (39%); Anal. calcd. for $C_{13}H_{14}O_4$ (234.25): C, 66.66; H, 6.02. found: C, 66.61; H, 5.99.


While the present invention has been described in connection with what are considered the most practical and preferred embodiments, it is understood that this invention is not limited to the disclosed embodiments but is intended to cover various arrangements included within the spirit and scope of the broadest interpretation and equivalent arrangements.

What is claimed is:

1. A method for preparing a coumarin compound of formula (F), in which \mathbb{R}^1 , \mathbb{R}^2 , and \mathbb{R}^3 are independently H, $\mathbb{C}_1 \sim \mathbb{C}_7$ alkoxy, $\mathbb{C}_1 \sim \mathbb{C}_7$ alkyl, phenoxy, benzyloxy, or a halogen atom; \mathbb{R}^4 is an alkyl group; and Ar is an optionally substituted aryl group,



the method comprising: treating a chromene compound having the following formula (E)



with an acid in the presence of water.

2. The method of claim **1**, wherein \mathbb{R}^4 is a \mathbb{C}_1 - \mathbb{C}_4 alkyl group.

3. The method of claim **1**, wherein Ar is unsubstituted aryl, haloaryl, alkylaryl, or alkoxyaryl.

4. The method of claim **3**, wherein Ar is phenyl, halophenyl, alkoxyphenyl, or alkylphenyl.

5. The method of claim **4**, wherein Ar is phenyl, 4-fluorophenyl, 4-chloro-phenyl, 4-bromo-phenyl, 4-methyl-phenyl, 4-methoxy-phenyl or 3-methoxy-phenyl.

6. The method of claim **2**, wherein R^1 , R^2 , and R^3 are independently H, Cl, Br, benzyloxy, or methoxy; and R^4 is methyl, ethyl, i-propyl, or n-butyl.

7. The method of claim 1, wherein the acid is selected from the group consisting of HCl, HBr, HI, CH_3CO_2H , and combinations thereof.

* * * * *